XCLINICAL
21.1.2021 14:02:05 CET | Business Wire | Press release
XClinical, a leading vendor of eClinical software has announced a merger with France-based Carenity, a social platform supporting patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system. All three companies are long-established, leading providers in their respective markets. The group is financed by German Private Equity firm BID Equity. Together, the three businesses will form a new, innovative data science company, powered by cutting edge technology. The group brings best in class data science and eClinical software solutions together, delivering end-to-end coverage of the clinical development process for their 150+ customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.
Biopharma, Medical Device as well as Academic sponsors and CROs worldwide will benefit from progressive and cost-efficient solutions such as feasibility studies, Real World Evidence data collection, patient recruitment, market access support in combination with EDC, CTMS, IWRS, eTMF, RBM and eCOA.
About XClinical
XClinical, a leading international provider of eClinical software solutions, has been the first acquisition in BID Equity’s Life Sciences portfolio. The company was founded 2002 in Munich, Germany with a vision to build a new EDC system leveraging CDISC standards to accelerate the database build and reduce data management programming efforts. XClinical’s Marvin is one of the world’s most established eClinical solutions, helping clinical study sponsors and CROs harness the power of their data to better manage clinical trials.
About Carenity
Carenity is a leading social platform supporting 500,000 patients and caregivers worldwide, across 1,000 chronic and rare diseases.
Through its award-winning platform and data science expertise, Carenity provides direct, timely and compliant access to patient real-world data. Founded in 2011 and headquartered in Paris, Carenity offers unique solutions for Real-World Evidence, Clinical Trial Optimization as well as Scientific Communication.
About Fortress Medical Systems
Fortress Medical Systems was founded in 1997 with the launch of Clindex®, one of the first integrated software systems designed for clinical trials. Over the years, Clindex® has been used to support medical device pharmaceutical, diagnostic and combination product studies. By working closely with their customers, the Fortress Medical team managed to grow the functionality of Clindex® so it is one of the most flexible and comprehensive systems on the market today. The client base spans the world. As a testament to the scalability of Clindex®, clients range from Fortune 500 corporations to small, start-up companies and include many contract Clinical Research Organizations as well.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 07:00:00 CEST | Press release
New three-year ARCADIA long-term extension data demonstrate that Nemluviois well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis1 The findings, to be shared at EADV 2026, show that up to 91% of patients achieved at least 75% improvement in eczema severity, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life at Week 1521 Additional analyses to be presented further establish itch and skin lesions as central drivers of sleep disturbance and overall quality of life impairment in prurigo nodularis and atopic dermatitis2,3 Collectively, these data reinforce our understanding of the long-term efficacy and safety profile of Nemluvio and underscore Galderma's long-standing commitment to improving the outcomes that matter most to patients with atopic dermatiti
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 07:00:00 CEST | Press release
Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8 More than 2.5 times as many patients treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16 compared to deucravacitinib Additional analyses from the pivotal LATITUDE PsO 3001 and 3002 studies showed durable skin clearance and rapid and continued improvements in patient-reported itch and quality of life Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zaso
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 06:16:00 CEST | Press release
The partnership was first launched in Indonesia, reaching about 10 million users, with plans to expand to more markets. Antom consolidates billing, tax, risk management, marketing and account services, covering the subscription lifecycle for AI companies. Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extens
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 06:00:00 CEST | Press release
British deep-tech company Signaloid joins CERN openlab as an Industrial Member, contributing its probabilistic computing technology to the CERN openlab Heterogeneous Architectures Testbed.CERN and Signaloid will jointly evaluate whether Signaloid's UxHw® technology can accelerate Monte Carlo event generation for the High-Luminosity Large Hadron Collider.The collaboration reflects a broader shift towards heterogeneous computing architectures designed to meet the growing demands of next-generation scientific computing. British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press
FPT Named in Forrester’s The SAP Services Landscape Report30.9.2026 05:00:00 CEST | Press release
Global technology corporation FPT has been included among the notable providers in The SAP Services Landscape, Q3 2026, published by Forrester Research, Inc. The report provides an overview of SAP services providers, examining their market focus, geographic presence, and business specializations to support enterprises in evaluating potential technology partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929359531/en/ The report includes FPT as a systems integrator with an Asia Pacific geographic focus and an industry focus spanning financial services and insurance, healthcare, and manufacturing. FPT identified SAP Business Data Cloud, SAP Enterprise Resource Planning (ERP), and SAP Supply Chain Management (SCM) as its three primary extended business scenario focus areas, what FPT believes reflects its emphasis on modernizing core enterprise systems and enabling more integrated, data-driven operations. Building on mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom